Laurus Labs Ltd has announced the acquisition of a 52% stake in SI & C Resins Private Limited for Rs 32.5 crore. This move aims to vertically integrate the company’s peptide manufacturing operations by securing local access to critical resins and chromatography gels. Laurus Labs has also committed to a potential further investment of Rs 30 crore to support future scaling of these manufacturing capabilities.
Laurus Labs Expands Peptide Strategy With SI&C Resins Buy
52% equity stake acquired for Rs 32.5 crore.
Future investment option of up to Rs 30 crore secured.
Reader Takeaway: Vertical integration of peptide resins secures supply chain, though full operational scale-up remains a long-term execution milestone.
What just happened
Laurus Labs has entered into a definitive agreement to acquire a 52% stake in SI & C Resins Private Limited (SI&C) for a total consideration of Rs 32.5 crore. The transaction is structured as a primary acquisition, valuing the target at Rs 30 crore on a pre-money basis. The deal is expected to be finalized within the current financial year.
Why this matters
This acquisition is a strategic move to vertically integrate Laurus Labs’ peptide manufacturing business. By gaining control over SI&C’s indigenous production of resins and chromatography gels—essential components for solid-phase peptide synthesis (SPPS)—Laurus Labs aims to reduce dependency on external suppliers and stabilize its production costs. The company further plans to leverage the target's technical expertise to establish large-scale manufacturing infrastructure.
The backstory
SI&C, a relatively new entity incorporated in July 2026, is taking over the operations of an existing partnership firm. The target firm reported a turnover of Rs 3.55 crore in FY 2024-25 and Rs 4.05 crore in FY 2025-26. It specializes in high-quality polymer and silica-based products utilized in peptide synthesis and ion exchange processes.
Risks to watch
Investors should monitor the execution risk associated with scaling SI&C's operations. While the company intends to build a large-scale plant, the successful integration of these manufacturing processes into Laurus Labs’ existing pharmaceutical ecosystem is critical for realizing the projected growth benefits.
What to track next
The company has secured an option to invest an additional Rs 30 crore in future securities of SI&C. Watching the timeline for the commissioning of the proposed large-scale resin manufacturing plant will be a key performance indicator for shareholders to assess the long-term ROI of this investment.